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ABSTRACT: Selenium (Se) incorporated into organic frameworks has demonstrated anticancer activity 
against several cancer types. One of the drawbacks of most of these constructs is their poor solubility 
and bioavailability, which can be overcome with the use of suitable nanocarriers. We have synthesized a 
series of 5-substituted amide selenodiazoles, based on the parent structure of ebselen, an organoseleni-
um drug with proven cytoprotective activity, and solubilized them in polymeric micelles of poloxam-
ines, poly(ethylene oxide)-poly(propylene oxide) X-shaped tetrablock-copolymers. Scattering methods 
(SANS and DLS) were employed to characterize the micellar nanocarriers. MTT biological evaluation 
highlights the selectivity of the Se-compounds towards cancer cells, with MCF-7 standing as the most 
responsive line. The alkylation of the heterocycle with a 12-carbon hydrophobic tail displays the highest 
activity, showing a 100-fold increase with respect to ebselen. This compound also exhibits the greatest 
increase in solubility in poloxamine micelles, overall resulting in a one-fold increase in activity with 
respect to the non-formulated form, making it a hit compound for further optimization. 
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ABSTRACT: Selenium (Se) incorporated into organic frameworks has demonstrated anticancer activity against several cancer 
types. One of the drawbacks of most of these constructs is their poor solubility and bioavailability, which can be overcome with the 
use of suitable nanocarriers. We have synthesized a series of 5-substituted amide selenodiazoles, based on the parent structure of 
ebselen, an organoselenium drug with proven cytoprotective activity, and solubilized them in polymeric micelles of poloxamines, 
poly(ethylene oxide)-poly(propylene oxide) X-shaped tetrablock-copolymers. Scattering methods (SANS and DLS) were employed 
to characterize the micellar nanocarriers. MTT biological evaluation highlights the selectivity of the Se-compounds towards cancer 
cells, with MCF-7 standing as the most responsive line. The alkylation of the heterocycle with a 12-carbon hydrophobic tail dis-
plays the highest activity, showing a 100-fold increase with respect to ebselen. This compound also exhibits the greatest increase in 
solubility in poloxamine micelles, overall resulting in a one-fold increase in activity with respect to the non-formulated form, mak-
ing it a hit compound for further optimization.  
1. Introduction 
Selenium (Se) is a micronutrient for humans; low plasma 
levels have been linked to a high incidence of several can-
cers1,2,3,4. Nevertheless, outcomes from the SELECT trial 
(Selenium and Vitamin E Cancer Prevention Trial) have given 
rise to some controversy about this relationship5. One of the 
main weaknesses of this trial was the chemical form used to 
deliver selenium (namely, L-selenomethionine). This alone 
could explain the unexpected failure of the SELECT trial since 
it is well documented that Se speciation is critical for its bio-
logical effects6,7,8. Indeed, some Se derivatives can be metabo-
lized to form selenocysteine, a Se amino acid that can be in-
corporated into 25 different selenoproteins. Most of the sele-
noproteins play essential roles in human health and low levels 
have been reported in several diseases 9,10,11,12. At the same 
time, other Se derivatives can be metabolized to methylselenol 
(CH3SeH) or to hydrogen selenide (H2Se); both present anti-
tumor activities, different than those from selenoproteins6. The 
activity of Se derivatives occurs through several mechanisms, 
some of them are not fully understood to date13. Taking into 
account all these considerations, it is clear that the activity of 
Se is dependent on the specific constructs in which it is incor-
porated, and the failure of some Se compounds should not be 
generalized to all Se derivatives. Recently, our group and 
many others have demonstrated that the incorporation of Se 
into organic frameworks, in particular small molecules such as 
selenocyanate, diselenide, selenourea or selenide, confers 
unique and very valuable properties against a range of diseas-
es14,15, and demonstrate anticancer activity against different 
cancer types16,17,18. Among these small Se-containing mole-
cules, Se heterocycles have demonstrated low toxicity for 
healthy cells, along with promising anticancer effects. Ebselen 
is one of the most well studied Se heterocyclic compounds in 
cancer19,20.  
One of the limitations of most Se-based drugs however is their 
poor solubility and bioavailability, which can be overcome 
with the use of suitable nanocarriers21. Polymeric micelles 
based on polyethylene oxide (PEO) and polypropylene oxide 
(PPO) are emerging as promising nanocarriers, displaying a 
large array of architectures and properties, in addition to dis-
playing biological inhibitory activity towards drug efflux 
transporters of the ATP-binding cassette22,23. Tetronic® is the 
trade name of BASF for poloxamines, a family of X-shaped 
amphiphilic copolymers based on PEO and PPO. Each of the 
four arms comprises a PEO and a PPO block, which are con-
nected by a central ethylene diamine group. This morphology 
drives self-assembly into micelles with a lipophilic core (PPO 
blocks) and a hydrophilic outer shell (PEO blocks), which is 
highly hydrated. The number of PO and EO units forming the 
arms varies, affording a range of molecular weights and hy-
drophilic-lipophilic balance (HLB), and consequently a rich 
phase behavior and properties24,25,26. If the configuration of the 
blocks is inverted, the resulting amphiphile is called a “re-
verse” poloxamine (Tetronic-R). The core of the aggregates 
offers a non-polar environment for the encapsulation of hy-
drophobic, poorly water-soluble drugs, while the protonable 
amino connector affords pH-responsiveness of the central 
moiety and thus controllable release of the cargo.  
Within this framework, we have synthesized a family of sele-
nodiazole derivatives bearing a hydrocarbon chain of variable 
 length (from 3 to 12 carbon atoms, SE3-SE12). This selenodi-
azole skeleton was chosen based on its similarity with ebselen 
(also known as PZ51, DR3305, or SPI-1005), and our previous 
experience on the antitumor and leishmanicidal in vitro activi-
ty of selenodiazole derivatives substituted on 5-position with 
different amides27,28. The synthetic strategy to obtain selenodi-
azole derivatives is outlined in Scheme 1.  
 
Scheme 1. Synthesis pathway for compounds SE3, SE4, SE5, 
SE6 and SE12. a) SeO2, 260 °C, solid phase, 1h. b) SOCl2, reflux, 
2h. c) R-NH2 (R: propyl (SE3), butyl (SE4), pentyl (SE5), hexyl 
(SE6), dodecyl (SE12)), CHCl3, TEA, r.t., 48h. 
These selenocompounds were formulated with two selected 
poloxamines, T904 (15 EO, 17 PO per arm, Mw 6,700) and 
T1107 (60 EO, 20 PO per arm, Mw 15,000), and their combi-
nations with T90R4, which presents a “reverse” structure 
compared to T904, bearing its PPO blocks on the outer parts 
of the four arms. T904 and T1107 were chosen according to 
their different HLB (12-18 and 18-23, respectively) and capac-
ity of T1107 to form gels, thus widening the scope of formula-
tions to injectable thermogels. The combined use of the re-
verse poloxamine in the mixed micelles is based on the hy-
pothesis that the incorporation of a hydrophobic amphiphile, 
which, on its own does not aggregate into micelles, can lead to 
an enhanced hydrophobic locus within the nanoaggregates 
and, consequently, a higher solubilization capacity of the 
selenocompounds. Although there are numerous routes of 
administration for chemotherapeutic drugs, i.e. intramuscular, 
intra-arterial or intrathecal among other, and ideally oral, the 
vast majority of these drugs are administered intravenously 
(i.v.), which would be the preferred route of administration for 
the new derivatives presented here. In this framework, the 
poloxamine micelles could help to overcome future issues in 
the pre-clinical development of selenodiazoles. 
 
2. Materials and methods 
2.1. Synthesis of the selenocompounds 
Compounds derived from benzo[c][1,2,5]selenodiazole were 
synthesized in the solid phase by cyclization of 3,4-
diaminobenzoic acid with SeO2 at high temperature and con-
stant stirring. The product is reacted with an excess of thionyl 
chloride under reflux conditions, yielding chlorination of the 
acid. The formation of the amide derivative follows a nucleo-
philic acyl substitution in the presence of triethylamine. Final 
products account for amides with a linear 3- (SE3), 4- (SE4), 
5- (SE5), 6- (SE6) and 12- (SE12) carbon chain (see SI for 
details of the synthesis and compound characterization). 
Analytical thin-layer chromatography (TLC) was conducted 
on E. Merck silica gel 60 F254 plates, 250 µm thickness and 
detection at 254 nm. Compounds were purified by chromato-
graphic column using the solvent mixtures specified in each 
case. Infrared (IR) spectra were registered using a Thermo 
Nicolet FTIR Nexus Euro spectrometer with OMNIC 6.0 
software. Products are obtained as solids and their spectra 
were recorded using transmission KBr pellets. Organic ele-
mentary analysis (CHN) was made in a LECO CHN-900 
microprocessor. The error interval admitted for each com-
pound is ± 0.5 %. Melting points were obtained using a Met-
tler FP82 heating stage and FP80 control unit, with a 5 ºC per 
minute heating rate. Nuclear magnetic resonance (NMR) spec-
tra were recorded on a Bruker 400 UltrashieldTM spectrome-
ter (1H, 400 MHz; 13C, 100 MHz) at room temperature (r.t.). 
Chemical shifts (δ) are expressed in parts per million (ppm) 
and coupling constants (J) in hertz (Hz). The following abbre-
viations are used to describe peak patterns when appropriate: s 
(singlet), d (doublet), t (triplet), q (quartet), qt (quintet), dd 
(double doublet), dq (double quartet) and br (broad). Fluores-
cence spectra were measured (Edinburgh Instruments FLS920 
spectrofluorimeter) to find the characteristic wavelengths of 
excitation and emission of the synthesized compounds in 
ethanol and water, so as to simulate the core and shell envi-
ronments of the poloxamine micelles. UV-Vis spectra were 
recorded (Agilent 8453 diode-array spectrophotometer) to 
obtain the characteristic molar absorptivity by the Beer-
Lambert law in ethanol and water, in the range 5·10-6 M to 
3·10-5 M. 
The polymeric surfactants, Tetronic 1107 (T1107) and 
Tetronic 904 (T904) were a gift from BASF, with reported 
compositions per arm 60 EO and 20 PO for T1107 (average 
molecular weight 15000 gmol−1) and 15 EO and 17 PO for 
T904 (average molecular weight 6700 gmol−1).  The “reverse” 
Tetronic 90R4 (T90R4) was purchased from Sigma-Aldrich 
(block composition 16 EO and 18PO). 
2.2. Characterization of the nanocarriers 
2.2.1. Small-Angle Neutron Scattering (SANS) 
Mixtures of T904 with T90R4, and T1107 with T90R4 (5, 15, 
25% w/w, in ratios of 80% direct Tetronic to 20% reverse 
Tetronic) were prepared at their natural pH (8.2), pH 3 (dipro-
tonated form) and pH 6 (monoprotonated form). Experiments 
were carried out on LOQ instrument at the ISIS spallation 
neutron source (ISIS, Rutherford-Appleton Laboratory, STFC, 
Didcot, Oxford). LOQ uses incident wavelengths from 2.2 to 
10.0 Å, sorted by time-of-flight, with a fixed sample-detector 
distance of 4.1 m, which provides a range of scattering vectors 
(q) from 0.009 to 0.29 Å-1. The samples were prepared in D2O 
(Aldrich, > 99.9% in D) to ensure sufficient contrast between 
the polymer and the solvent and then placed in clean disc-
shaped quartz cells (Hellma) of 1 mm path length, controlling 
the temperature from 20 to 50°C with an external thermostat. 
All scattering data were first normalized for sample transmis-
sion and then background-corrected using a quartz cell filled 
with D2O, and finally corrected for the linearity and efficiency 
of the detector response using instrument-specific software 
package. The data were then converted to the differential 
scattering cross-sections, expressed in absolute units of cm-1, 
using the standard procedures for LOQ. SANS curves were 
fitted using SasView 3.1.0 software29. Scattering curves from 
the poloxamines in their unimer form were fitted with a four-
arm star-shape (4SP) polymer model, while micelles were 
fitted to a core-shell sphere (CSS) model combined with a 
 hard-sphere structure factor (HS). When coexisting in solu-
tion, a mixed model of unimers and micelles was used by 
combining the above two models.  
2.2.2. Phase diagrams 
Aqueous solutions of T904 (1-25% wt%), T1107 (1-25 wt%) 
and mixtures of T904 with T90R4 as well as T1107 with 
T90R4 (5-25% wt% total concentration with 80% direct 
Tetronic/20% reverse Tetronic) were placed into a water bath 
at an initial temperature of 25 ºC. The samples were gradually 
heated up by 5 ºC increments up to 80 ºC. All samples were 
prepared at their natural pH (ca. 8.2), pH 3 and pH 6, by add-
ing the required amount of concentrated HCl.  
2.2.3. Dynamic Light Scattering (DLS) 
Size distributions of the poloxamine in water were obtained 
with a photon correlation spectrometer Malvern Zetasizer 
Nano, with a laser wavelength of 633 nm. The samples were 
filtered prior to the measurements by 0.22 m Millex syringe 
PVDF filters onto semi-micro glass cells, and the temperature 
of the samples controlled with 0.1˚C accuracy by the built-in 
Peltier in the cell compartment. The viscosity and refractive 
index of the solvent at different temperatures were taken into 
account to obtain the particle size distribution from the analy-
sis of the autocorrelation function, which was performed with 
the Zetasizer software in the high-resolution mode to better 
distinguish overlapping distributions.  
2.2.4. Solubilization studies 
An excess of compound (SE3, SE6 and SE12) was introduced 
in vials with 15% w/w solutions of polymer (T904, T1107, 
T904+T90R4 (80%/20% direct/reverse Tetronic), 
T1107+T90R4 (80%/20% direct/reverse Tetronic)) or in pure 
water. Samples were left to stir in the water bath at 40 ºC and 
measured after 72 and 92 h to assure maximum solubility was 
reached. Drug concentration was obtained from the absorb-
ance data using each poloxamine system as a blank, and the 
previously established Beer-Lambert law equation. 
2.3. Cytotoxicity studies 
Synthesized selenodiazoles were tested in vitro against cul-
tured cells of leukaemia (CCRF-CEM), colon (HT-29), lung 
(HTB-54), prostate (PC-3) and breast (MCF-7) cancer by 
means of the tetrazolium assay (MTT). All the compounds 
were also tested for toxicity in a mammary gland cell culture 
derived from non-malignant cells (184B5). All cells were 
defrosted and maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin at 37 ºC and 5% CO2. 1 
mmol of compound was diluted in 1 mL DMSO to a concen-
tration of 10-2 M and filtered with 0.22 µm Millipore filter to 
ensure sterility. Serial dilutions were made using non-
supplemented media to achieve concentrations from 10-3 to 10-
7 M. 96-well plates were seeded with 100 µL of cellular sus-
pension (100 cells/ µL), 80 µL of media and 20 µL of com-
pound solution, obtaining final samples of concentration 10-4-
10-8 M. Each sample was evaluated in quadruplicate measure-
ments and repeated in three independent cell samples. Non-
supplemented media was used as a blank and controls were 
performed for each cell line. The same methodology was 
followed to test three representative compounds (SE3, SE6, 
SE12) encapsulated in polymer micelles (T904, T1107 and 
T904+T90R4 (80%/20% direct/reverse Tetronic)). In this case, 
samples were prepared in 15% (w/w) poloxamine and dilu-
tions performed to obtain samples at 10-3 to 10-7 M, following 
the previously described protocol. Blanks were made with 
each poloxamine system. 
3. Results and discussion 
3.1. Structural characterization of the nanocarriers 
Analysis of phase diagrams (SI, Tables S1A and S1B) shows 
that the most hydrophilic T1107 forms a gel at around 35 ºC 
and 25%, while the requirements for T904 to form gel are 
more extreme. In the mixed systems, the incorporation of 
T90R4 hinders the formation of a gel phase for T904 and 
shifts the sol-gel transition by 5 ºC for T1107 at 25%T1107. 
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Figure 1. (A) DLS Intensity size distribution for T1107+T90R4 
2% (1:1 mass ratio) as a function of temperature. Only unimers 
are present up to 25 ºC, a mixture of unimers and micelles at 
intermediate temperatures (30-40 ºC) and only micelles over 40 
ºC. (B) SANS curves for the T1107+T90R4 mixture and T1107 
alone at 20 and 50 ºC (solid lines are fits to the 4SP and CSS 
models described in the text) 
Precise structural information on the polymeric nanocarriers 
can be obtained from small-angle neutron scattering (SANS) 
and dynamic light scattering (DLS). As an example, Figures 
1A and 1B show the DLS size distribution and SANS scatter-
ing patterns for mixtures of T1107 with the reverse polox-
amine as a function of temperature, for 2% of each Tetronic. 
At 20 ºC, both surfactants are in the form of unimers, and 
 SANS patterns under these conditions are suitably described 
by a four-arm-star polymer model (4SP), with an average 
radius of gyration of 25 Å, matching the hydrodynamic radii 
observed by DLS. As the temperature increases, upon reaching 
the critical temperature (CMT), unimers self-organise to form 
micelles, behaviour typical of PEO-PPO based surfactants24-26. 
At 30ºC a new distribution in the DLS size distribution ap-
pears at 30 nm, corresponding to the mixed micelles, although 
its contribution in mass is still very low. At higher tempera-
ture, unimers coexist with the micelles, and the contribution of 
the peak corresponding to the unimers concomitantly reduces, 
while the broad peak due to the micelles becomes narrower 
and shifts to smaller sizes. At 40ºC mixed micelles are fully 
formed and there is just one peak at ca. 15 nm in size. The 
solubilization of the reverse poloxamine T90R4 in the micelles 
is evidenced by a shift of the phase separation, from 36 ºC for 
T90R4 alone, to ca. 60 ºC when mixed with either T904 or 
T1107. This effect can be observed in the phase diagrams at a 
higher direct/reverse Tetronic mass ratio of 4:1 (SI, Table S1A 
and S1B). 
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Figure 2. SANS patterns for direct and reverse poloxamine solutions at varying temperatures and concentrations. (A) T904+T90R4 5% as 
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model used is CSS-HS. (D) T1107+T90R4 at 40 ºC, concentrations 5, 15, and 25%; models used are CSS+HS (green, blue) and a body 
centre cube (bcc) paracrystal (red). 
Micelles are appropriately described by a core-shell spherical 
model (CSS) combined with a hard sphere structure (HS) 
factor, allowing the estimation of the geometrical parameters 
and hydration state of micellar core and shell (Figure 2A to 
C)24.  
The parameters derived from the fits (Table 1) show that sub-
stituting a direct unimer by its reverse counterpart does not 
have a significant impact on the overall size of the micelles. 
Increasing the polymer concentration, instead, induces a slight 
shrinkage of the hydrophilic shell. The scattering length densi-
ty (sld) of the core, which was set as a floating parameter in 
the fits, reaches values close to the sld of PPO (3.4·10-7 Å-2), 
reflecting a dehydrated hydrophobic core (no penetration of 
solvent). Instead, the sld of the shell tends to that of pure sol-
vent (6.36·10-6 Å-2), showing a very high extent of hydration 
of the PEO blocks. It is worth mentioning that the shell sld is 
lower in all cases than the corresponding value for the pure 
poloxamine, indicating more permeability to the solvent. At 
high concentrations, gels are formed (Tables S1A and S1B). 
Thus, at 25% T1107 + T90R4 (4:1 ratio, 40 ºC), the long-
range order responsible for gelation is reflected by a sharp 
diffraction peak in the 0.07-0.09 Å-1 q-region (Figure 2D), not 
observed for T904. The analysis of the SANS data by means 
of a paracrystal bcc model yields a cell parameter of 167 Å, 
which matches the dimensions obtained with the same model 
for T1107 alone. A core size of 35 Å is obtained for the 
packed micelles, which is very similar to that of the mixed 
micelles under dilute conditions (Table 1), and to T1107 alone 
at the same concentration and temperature. The behavior of 
T904 in combination with 90R4 follows the same trend, as 
shown in Table 1. 
 Table 1. Micellar structural parameters at 40 oC in D2O obtained 
from SANS data analysis: Rc (core radius), t (shell thickness),  
(volume fraction from the hard-sphere potential), s (scattering 
length density of the shell). In the mixed systems, the concentra-
tion is given as the total wt %, at a 4:1 weight ratio. 
Polymeric micelles Rc / Å t / Å  s 106 / Å-2 
T904 8% 35 21 0.18 5.87 
T904-T90R4 5% 35 26 0.09 6.22 
T904-T90R4 15% 35 21 0.27 6.23 
T904-T90R4 25% 34 19 0.40 6.20 
T1107 5% 34 45 0.18 5.94 
T1107-T90R4 5% 34 44 0.11 6.08 
T1107-T90R4 15% 33 37 0.39 6.02 
 
In the view of exploiting the pH to control the delivery of the 
cargo from the micellar core, the effect of pH on the morphol-
ogy of the aggregates was studied next. Upon a reduction of 
the pH below the second pKa (pH 6), the partial protonation of 
the central ethylene diamine connector leads to a decrease of 
the scattering. A further reduction below the first pKa (pH 3) 
yields curves reminiscent of the unimer form, with radii of 
gyration similar to those of the respective unimers forming the 
micelles at its natural pH (pH 8.2), as obtained from fits to a 
4SP model. Overall, this means that the protonation of the 
amino groups causes strong electrostatic repulsion between the 
direct Tetronic unimers in the core, and the reverse Tetronic in 
the shell. This destabilizes the mixed micelles, leading first to 
a mixture of free unimers and aggregates (pH 6), and then to a 
full rupture of the structures where only unimers are present 
(pH 3) (SI, Figure S1).  
Overall, the structural analysis on the mixed micelles shows 
that the copolymer with the reverse configuration, largely 
insoluble on its own, can be incorporated inside the direct 
micelles. The dimensions of the micelles are not impacted by 
substituting up to 20% in weight by the reverse structure. The 
hydrophobic core presents a high degree of packing of the 
PPO blocks, while the main impact of incorporating the re-
verse poloxamine is a slight increase of the hydration of the 
PEO shell. Hence, from a structural viewpoint, any of the 
combinations is suitable for the solubilization of a hydropho-
bic cargo. 
3.2. Drug Encapsulation 
The solubilization of selected organoselenium constructs 
(SE3, SE6, SE12) was studied in direct poloxamines (T904, 
T1107) and in their mixtures with the reverse copolymer 
(T904+T90R4, T1107+T90R4) (Figure 3). As expected, the 
construct with the shorter alkyl chain, SE3, displays the high-
est solubility in water at 4.92·10-4 M. Increasing the length of 
the hydrocarbon tail drastically reduces solubility, with values 
of 3.5·10-5 M and 9·10-6 M obtained for SE6 and SE12. Incor-
poration into the polymeric nanocarriers enhances the solubili-
ty (Figure 3), with the best solubilization observed with the 
smaller T904. The addition of the reverse Tetronic T90R4, 
hypothesized to expand the hydrophobic locus of solubiliza-
tion, instead slightly reduces the total drug loading. The effect 
is more pronounced with the long chain organoselenium con-
structs (SE6 and SE12), whereas for the less hydrophobic 
compounds (SE3), a slight improvement is noted in the mixed 
T1107 micelles compared to T1107 alone. 
Overall, while the incorporation of the reverse polymer leaves 
micellar dimensions virtually unchanged, a possible rear-
rangement of the polymer chains (in particular a more open 
and hydrated corona) may lead to a different environment, less 
favorable to drug solubilization, at least for the compounds 
synthesized here.  
3.3. Anticancer activity and selectivity 
The drug constructs were evaluated for their cytotoxic activity 
using MTT assays against a panel of five human tumor cell 
lines as a representative selection of liquid, solid and hor-
mone-dependent tumors, including lymphocytic leukemia 
(CCRF-CEM), lung carcinoma (HTB-54), colon carcinoma 
(HT-29), prostate adenocarcinoma (PC-3) and breast adeno-
carcinoma (MCF-7) (SI, Figure S2). In order to evaluate the 
selectivity of the drugs, their toxicity was also assessed against 
a non-malignant cell line derived from normal breast tissue 
(184B5). The results are expressed in terms of IC50, the con-
centration that reduces by 50% the growth of treated cells with 
respect to untreated controls. 
  
Figure 3. Solubility studies. Final concentration (M) of SE3, SE6 
and SE12 after 3 days at 40 ºC in water, T904, T904+T90R4, 
T1107 and T1107+T90R4. Tetronic concentrations used are 15 % 
w/w, as for the biological assays. Concentrations of SE6 and 
SE12 are multiplied by a factor of ten. 
SE12 shows a remarkable cytotoxic profile, together with 
selectivity, under our experimental conditions, with IC50 val-
ues lower than 1 µM in MCF-7 and PC-3 and higher than 100 
µM for 184B5 (Table 2). This represents a 65 and 100-fold 
increase (for MCF-7 and PC-3, respectively) compared to the 
reference drug ebselen. These results suggest that the long 
alkyl lateral chain plays a key role in the activity of the drug, 
with 12 atoms of carbon being the optimal length. In addition, 
SE4 and SE12 combine potency and selectivity, a highly at-
tractive feature for anticancer drugs, whose toxic side effects 
are a limitation to their use.  
 
 
 Table 2. MTT results for leukaemia (CCRF-CEM), colon (HT-
29), lung (HTB-54), prostate (PC-3) and breast (MCF-7) cancer 
cells as well as non-cancer breast tissue cells (184B5). 
 
IC50 / µM 
CCRF-
CEM 
HT-29 
HTB-
54 
PC-3 
MCF-
7 
184B5 
SE3 91.9 >100 >100 >100 >100 >100 
SE4 >100 >100 >100 >100 11.1 >100 
SE5 68.4 >100 >100 >100 84.3 >100 
SE6 45.7 81.2 >100 84.4 >100 >100 
SE12 >100 11.5 >100 0.20 0.90 >100 
Ebselen 57.1 >100 68.8 >100 58.8 30.1 
 
In a further step, and since the poor solubility of Se com-
pounds is a limitation to their clinical use, the activity of the 
constructs was assessed in formulations with the different 
Tetronics and combinations with the reverse one. MTT assays 
on the most responsive cell line (MCF-7) were repeated on 
representative compounds (SE3, SE6 and SE12) encapsulated 
in T904, T904+T90R4 and T1107 micelles (Figure 4). Table 3 
reveals a remarkable decrease of the IC50 values for the com-
pounds loaded in T904 and T904+T90R4 mixed micelles in 
comparison to the non-formulated constructs, particularly 
noticeable for SE12 (Figure 4), (SI, Figures S3, S4 and S5). 
While T1107 and T90R4 show some cytotoxicity on their 
own, T904 has minimum effect on the cells, making it the 
ideal candidate for the development of delivery systems (SI, 
Figures S3, S4 and S5).  
Considering together the cell growth inhibition, it can be stat-
ed that the substitution of the selenodiazole framework in 
position 5 with aliphatic chains result in an outstanding in-
crease of the anticancer activity for this class of compounds. A 
comparison of the reported cytotoxic activity for the unsubsti-
tuted carboxylic acid ([1] in Scheme 1) and carboxamide27 
with the derivatives presented herein reinforce this molecular 
design, making it a very promising approach to develop more 
potent and selective antitumor agents. 
To our knowledge, the only Se-containing compound to date 
modified to form nanocapsules is selol incorporated in a pol-
ymeric shell composed of poly(methyl vinyl ether-co-maleic 
anhydride) (PVM/MA). Nonetheless, this modification yielded 
only a slight increase in the cytotoxicity in lung cells after 72 h 
of treatment30. Accordingly, the use of poloxamines in seleno-
diazole derivatives achieved a much higher increase in the 
antitumor activity, making this construct very promising. 
   
Figure 4. Cytotoxicity results on SE12 encapsulated in Tetronic systems (15% w/w) and tested against breast cancer MCF-7 cell line. 
From left to right SE12 in T904, in T904+T90R4 and in T1107. 
 
Table 3. IC50 values for encapsulated and non-encapsulated sele-
nocompounds SE3, SE6 and SE12. Results obtained by MTT 
assay performed on MCF-7 cells. 
 IC50 / µM 
 
No encapsula-
tion 
T904 T904+T90R4 T1107 
SE3 >100 6.20 1.33 46.85 
SE6 >100 1.38 0.52 >10 
SE12 0.9 0.05 0.03 >1 
 
 
4. Conclusions 
In summary, based on the importance of Se for human health 
and positive evidence from the literature on Se-heterocycles 
and in particular the commercial drug ebselen, we have creat-
ed a small library of selenocompounds, 5-substituted amide 
selenodiazoles with increasing hydrophobicity, derived from 
alkyl lateral chains ranging from 3 to 12 carbon atoms. Given 
the low solubility and poor bioavailability of Se-based com-
pounds being a barrier towards their clinical use, our con-
structs were encapsulated in PEO-PPO tetrablock copolymer 
micelles, namely, Tetronics T904 and T1107, and their com-
bination with the reverse copolymer T90R4, which has hydro-
phobic blocks as end blocks, and is poorly soluble. The incor-
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 poration of these new constructs within the micelles largely 
enhanced their solubility, thus offering a route towards higher 
bioavailability. Combined SANS and DLS studies allowed us 
to characterize the nanoaggregates as presenting a core-shell 
morphology, with a dense PPO core and a largely hydrated 
PEO corona. The largely insoluble reverse Tetronic T90R4 is 
incorporated within the micelles (up to 20% of the total 
weight), and, aside from a higher hydration of the corona, does 
not impact the structural parameters of the micelles, albeit 
slightly reducing the drug loading within the aggregates. Bio-
logical evaluation highlights the selectivity of the constructs 
towards cancer cells, MCF-7 being the most responsive line. 
The construct with the longest alkyl side chain, SE12, shows 
the best activity by far, with up to a 100-fold increase with 
respect to ebselen. A further improvement of the activity is 
achieved by encapsulation within the polymeric micelles. The 
smaller and more hydrophobic T904 displays the highest solu-
bilization capacity, combined to the highest activity enhance-
ment, pointing to the combination of this nanocarrier with 
SE12 as a promising candidate for further optimization. 
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